Medicare Enrolled
Dr. Reza Farhangfar, MD
Pulmonary Disease · Wayne, NJ
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Farhangfar from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Farhangfar?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Farhangfar
Dr. Reza Farhangfar is a pulmonary disease specialist in Wayne, NJ, with 19 years of NPI registration. Based on federal Medicare data, Dr. Farhangfar performed 3,797 Medicare services across 1,855 unique beneficiaries.
Between the years covered by Open Payments, Dr. Farhangfar received a total of $4,365 from 34 pharmaceutical and/or device companies across 294 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Farhangfar is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 8% volume in NJ
$4,365 industry payments
Medicare Practice Summary
Medicare Utilization ↗3,797
Medicare services
Top 8% in NJ for pulmonary disease
1,855
Unique beneficiaries
$76
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~200 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
1,977 | $69 | $257 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
538 | $73 | $181 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
272 | $148 | $717 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
148 | $104 | $279 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
115 | $113 | $485 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
102 | $103 | $368 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
97 | $34 | $225 |
| Lung volume test using gas dilution or washout A test that measures the amount of air in your lungs by using a gas dilution or washout method. |
93 | $37 | $164 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
93 | $47 | $209 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
84 | $48 | $120 |
| Hemoglobin measurement A blood test that measures the amount of hemoglobin, the protein in red blood cells that carries oxygen. |
70 | $5 | $21 |
| Initial nursing facility care, high complexity An initial visit by a healthcare provider to a patient in a nursing facility involving a high level of medical decision making, lasting at least 45 minutes. |
49 | $160 | $594 |
| Chest cavity fluid aspiration A procedure to remove fluid from the space between the lungs and the chest wall using a needle or catheter. |
32 | $76 | $663 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
26 | $83 | $394 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
24 | $24 | $25 |
| Nursing facility visit, low complexity A daily follow-up visit for an existing patient in a nursing facility involving straightforward medical decision making. The visit requires at least 15 minutes of time if time is used to determine the level of care. |
22 | $63 | $246 |
| Flu vaccine, high-dose High-dose seasonal influenza vaccine for adults aged 65 and older. Contains four times the antigen of standard-dose flu vaccines (60 mcg per strain), split-virus formulation, preservative-free, single-dose syringe. |
21 | $69 | $70 |
| New patient office visit, 15-29 minutes An initial office visit for a new patient lasting 15 to 29 minutes. This code is used when the total time spent on the date of the encounter meets this duration threshold. |
21 | $63 | $279 |
| Exercise-induced lung stress test A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising. |
13 | $30 | $124 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$4,365
Total received (2018-2024)
Avg $624/year across 7 years
Top 36% in NJ for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
34
Companies
294
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,331 (99.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$34 (0.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$158
2023
$556
2022
$563
2021
$866
2020
$565
2019
$932
2018
$725
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
GlaxoSmithKline, LLC.
$64
AstraZeneca Pharmaceuticals LP
$29
HARMONY BIOSCIENCES LLC
$19
Philips North America LLC
$16
Mylan Specialty L.P.
$15
Actelion Pharmaceuticals US, Inc.
$15
Top 3 companies account for 70.7% of 2024 payments
All-time payments by company (2018-2024) ›
GlaxoSmithKline, LLC.
$1,295
AstraZeneca Pharmaceuticals LP
$852
Boehringer Ingelheim Pharmaceuticals, Inc.
$332
Sunovion Pharmaceuticals Inc.
$277
Mylan Specialty L.P.
$231
JAZZ PHARMACEUTICALS INC.
$143
Insmed, Inc.
$126
Teva Pharmaceuticals USA, Inc.
$100
Philips Electronics North America Corporation
$98
Jazz Pharmaceuticals Inc.
$96
Janssen Pharmaceuticals, Inc
$64
Harmony Biosciences LLC
$64
Amgen Inc.
$62
Regeneron Healthcare Solutions, Inc.
$60
PFIZER INC.
$57
Mallinckrodt Hospital Products Inc.
$57
Axsome Therapeutics, Inc.
$47
Grifols USA, LLC
$44
GENZYME CORPORATION
$44
United Therapeutics Corporation
$35
Actelion Pharmaceuticals US, Inc.
$34
HARMONY BIOSCIENCES LLC
$33
Takeda Pharmaceuticals U.S.A., Inc.
$26
Novartis Pharmaceuticals Corporation
$26
Circassia Pharmaceuticals Inc
$23
PORTOLA PHARMACEUTICALS, INC.
$21
Advanced Respiratory, Inc
$20
Pulmonx Corporation
$17
Philips North America LLC
$16
Vanda Pharmaceuticals Inc.
$15
Shire North American Group Inc
$14
Merck Sharp & Dohme Corporation
$13
Mallinckrodt Enterprises LLC
$11
Genentech USA, Inc.
$11
Top 3 companies account for 56.8% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · (AK6) Vest Therapy · ACTHAR · ANORO · ANORO ELLIPTA · APTIOM · AREXVY · Arikayce · BEVESPI AEROSPHERE · BEVYXXA · BREO · BREO ELLIPTA · BREZTRI · BREZTRI AEROSPHERE · CHARTIS CATHETER · CINQAIR · DUPIXENT · Esbriet · FASENRA · GLASSIA · Hetlioz · LONHALA MAGNAIR · Life 2000 Ventilation System · NUCALA · OFEV · OPSUMIT · PAXLOVID · Perforomist · ProAir Digihaler · Prolastin-C Liquid · QVAR · SPIRIVA · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SUNOSI · SYMBICORT · Sunosi · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · Utibron · WAKIX · Wakix · Wellcentive Undiv · XARELTO · XOLAIR · XYREM · XYWAV · Xyrem · YUPELRI · Yupelri · ZERBAXA · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Pulmonary diseases within 10 mi
490
Per 100K population
94.5
County median income
$87,137
Nearest hospital
CHILTON MEDICAL CENTER
3.6 mi
3.6 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Farhangfar is a clinical cardiology specialist, with above-average Medicare volume (top 8% in NJ), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Farhangfar experienced with hospital follow-up visit, moderate complexity?
Based on Medicare claims data, Dr. Farhangfar performed 1,977 hospital follow-up visit, moderate complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Farhangfar receive payments from pharmaceutical companies?
Yes. Dr. Farhangfar received a total of $4,365 from 34 companies across 294 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Farhangfar's costs compare to other pulmonary diseases in Wayne?
Dr. Farhangfar's average Medicare payment per service is $76. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Farhangfar) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Wayne
Browse pulmonary diseases in Wayne ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in NJ
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in NJ
Which NJ pulmonary diseases receive the most from drug and device companies.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology